5 Prominent Players in the Methotrexate Drug Market, 2023

A derivative of folate called methotrexate works to delay the production of enzymes that synthesize nucleotides. It is a member of the group of anti-metabolites. The inhibition slows down cell division and inflammatory responses. It is used to treat cancer, psoriasis, and arthritis. Methotrexate is used to treat leukaemia and some forms of cancer of the breast, skin, head & neck, lung, or uterus because it prevents the proliferation of some cells in the body, particularly those that multiply quickly, like cancer cells, bone marrow cells, and skin cells. Adults with rheumatoid arthritis and severe psoriasis are also treated with methotrexate. Juvenile rheumatoid arthritis of the polyarticular course that is active in youngsters is also treated with it. When other medications have failed to work, methotrexate may be prescribed.

In addition to suppressing the immune system, methotrexate is a medication that is frequently used to treat autoimmune diseases. Additionally, it is well known for its application in the management of ectopic pregnancy and medical abortions. The drug, which can be taken orally or delivered intravenously, has FDA approval.

According to Business Research Insights, the global methotrexate drug market size was valued at USD 532.4 million in 2022 with a CAGR of 2.7% and is expected to reach a valuation of USD 622.8 million by the year 2028.

Business Research Insights Presents The Top 5 Players In The Market

Obstruction In Operation Activities During COVID-19 To Impede The Market Growth

The COVID-19 epidemic has had unanticipated effects on every sector of the global economy. The national governments imposed strict lockdowns to lessen the pandemic's severity. Fighting the problems associated to COVID-19 transformed the focus of the entire economy. This had a negative impact on a number of industries, and the methotrexate market also experienced declining demand from all geographical areas. The interruption in the operation activities and supply-chain shock also caused a scarcity of API needed to manufacture methotrexate, which interrupted the drug's export-import trade and had a negative impact on the its market growth.

Business Research Insights Reports Top 5 methotrexate drug companies

1. Pfizer Inc. (U.S.)

Pfizer Inc. (Pfizer) was founded in 1849 by Charles Pfizer and Charles F. Erhart with the intention of discovering, developing, manufacturing, and marketing biopharmaceuticals. The business creates medicines to treat a range of diseases, including as cancer, inflammation, immunological disorders, chronic illnesses, and problems with the heart, metabolism, and pain. Additionally, it provides pharmaceutical drugs, biosimilars, sterile injectable drugs, contract manufacturing services, and active pharmaceutical ingredients (APIs).

2. Silvergate Pharmaceuticals, Inc. (U.S.)

Michael Beckloff co-founded Silvergate, a company that creates pediatric medications, in 2010. CutisPharma Inc. later acquired Silvergate, combining the two businesses to form Azurity Pharmaceuticals, a specialty pharmaceuticals firm that specializes in creating and marketing paediatric medications. The company's strategy is to develop novel therapies that outperform currently available options in terms of dosing precision, safety, and accessibility.

3. Apotex Inc. (Canada)

A global pharmaceutical firm, Apotex Inc. manufactures high-quality, fairly priced medications for patients.  Apotex is a major manufacturer of generic pharmaceuticals in Canada was founded in 1974 by Barry Sherman. The company consists of several divisions, such as Apotex Inc., which focuses on generics; Apobiologix, a division of Apotex Inc., which focuses on the development of biosimilars; and Global Active Pharmaceutical Ingredients (GAPI), a division of Apotex Inc., which manufactures active pharmaceutical ingredients (API) for Apotex and other companies.

4. Par Pharmaceutical (U.S.)

Par Pharmaceutical, Inc. is a generic pharmaceutical company. It specializes on non-oral dosage forms such nasal sprays, inhalers, patches, and many other alternative drug delivery systems, in addition to oral solid dosage forms with modified release. Its primary focus is on therapeutically similar ANDA-based treatments, while considering additional items on an individual basis. A wide range of branded and generic aseptic injectable products are developed, produced, and sold by Par Sterile Products.

5. Amneal Pharmaceuticals LLC (U.S.)

Amneal Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company with deepening portfolios in institutional injectables, biosimilars, and specific international markets. Its U.S. generics business is strong, its branded business is expanding, and it also has a strong institutional injectables business. Its generics portfolio of more than 250 drugs offers accessible, high-quality medications at reasonable prices that address critical medical requirements in the treatment of endocrinology, central nervous system disorders, and other therapeutic domains.

High Potential Of Methotrexate To Expand The Market Exponentially

The market players recognize the untapped potential in the methotrexate drug market and as a result, methotrexate has a wide range of applications and a tremendous amount of potential to treat critical conditions including to treat cancer or other illnesses that are extremely severe. The drug methotrexate is a powerful compound with high potential which is set to grow the methotrexate drug market.